Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00836173 | Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma | withdrawn | Phase 2 | 0 | Loyola UniversityOTHER | 1 | Mar 16, 2016 | clinicaltrials |
| NCT01528865 | Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 11, 2016 |
| clinicaltrials |
| NCT01249105 | MK-2206 for Recurrent Malignant Glioma | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT02014831 | Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)(PENILANE) | withdrawn | Phase 2 | 0 | Centre Leon BerardOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT01157039 | A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin | withdrawn | Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 0 | Feb 24, 2016 | clinicaltrials |
| NCT01994200 | Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients(ITCA-ThyCa) | withdrawn | Phase 1 / Phase 2 | 0 | Jewish General HospitalOTHER | 1 | Feb 23, 2016 | clinicaltrials |
| NCT00349518 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL | withdrawn | Phase 2 / Phase 3 | 0 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 17, 2016 | clinicaltrials |
| NCT01410708 | TORI 104 Pre-Surgical Dasatinib | withdrawn | Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT00414089 | Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL | withdrawn | Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT02521090 | EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Feb 15, 2016 | clinicaltrials |
| NCT01329289 | SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma | withdrawn | Phase 2 | 0 | University of PittsburghOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT02035124 | Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel | withdrawn | Phase 2 | 0 | SCRI Development Innovations, LLCOTHER | 1 | Feb 11, 2016 | clinicaltrials |
| NCT00024128 | Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma | withdrawn | Phase 2 | 0 | AIDS Malignancy ConsortiumNETWORK | 0 | Feb 3, 2016 | clinicaltrials |
| NCT00310128 | Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma | withdrawn | Phase 2 | 0 | AIDS Malignancy ConsortiumNETWORK | 0 | Feb 3, 2016 | clinicaltrials |
| NCT02452281 | Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Rabih SaidOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT01985893 | Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer(THOR) | withdrawn | Phase 2 | 0 | Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.OTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00984217 | Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies | withdrawn | Phase 2 | 0 | University of PittsburghOTHER | 1 | Jan 8, 2016 | clinicaltrials |
| NCT02140437 | Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC | withdrawn | Phase 2 | 0 | Fudan UniversityOTHER | 0 | Dec 29, 2015 | clinicaltrials |
| NCT01624493 | BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients | withdrawn | Phase 1 / Phase 2 | 0 | Hoosier Cancer Research NetworkOTHER | 3 | Dec 23, 2015 | clinicaltrials |
| NCT00343759 | Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy | withdrawn | Phase 2 | 0 | University of PennsylvaniaOTHER | 1 | Dec 11, 2015 | clinicaltrials |
| NCT02323516 | Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies.(ASPIDIA) | withdrawn | Phase 2 | 0 | Centre Francois BaclesseOTHER | 1 | Dec 8, 2015 | clinicaltrials |
| NCT00003273 | Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor | withdrawn | Phase 2 | 0 | NYU Langone HealthOTHER | 3 | Dec 3, 2015 | clinicaltrials |
| NCT00992173 | Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma | withdrawn | Phase 2 | 0 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 2 | Nov 26, 2015 | clinicaltrials |
| NCT02599090 | Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 6, 2015 | clinicaltrials |
| NCT02536495 | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Erin BertinoOTHER | 0 | Oct 30, 2015 | clinicaltrials |
| NCT00768131 | A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel | withdrawn | Phase 2 | 0 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00670150 | New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Oct 27, 2015 | clinicaltrials |
| NCT00874315 | Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL. | withdrawn | Phase 2 | 0 | Nationwide Children's HospitalOTHER | 1 | Oct 16, 2015 | clinicaltrials |
| NCT01263418 | Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | Oct 12, 2015 | clinicaltrials |
| NCT00227773 | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | Oct 8, 2015 | clinicaltrials |
| NCT00469976 | Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | Oct 8, 2015 | clinicaltrials |
| NCT00755157 | Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | University Hospital of CreteOTHER | 1 | Oct 7, 2015 | clinicaltrials |
| NCT01530984 | Ipilimumab and GMCSF Immunotherapy for Prostate Cancer | withdrawn | Phase 2 | 0 | Lawrence FongOTHER | 1 | Oct 5, 2015 | clinicaltrials |
| NCT00075413 | Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | The University of Texas Medical Branch, GalvestonOTHER | 0 | Oct 2, 2015 | clinicaltrials |
| NCT01598584 | Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 28, 2015 | clinicaltrials |
| NCT01180569 | Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Sep 25, 2015 | clinicaltrials |
| NCT01501604 | BKM120 in Cancers With PIK3CA Activating Mutations | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 0 | Sep 17, 2015 | clinicaltrials |
| NCT02053597 | TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen(TRIUMPH) | withdrawn | Phase 2 | 0 | Jules Bordet InstituteOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT01764009 | Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma(AIMM) | withdrawn | Phase 1 / Phase 2 | 0 | Valerio TherapeuticsINDUSTRY | 2 | Sep 11, 2015 | clinicaltrials |
| NCT01586182 | Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 4, 2015 | clinicaltrials |
| NCT01184287 | A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Tamir Biotechnology, Inc.INDUSTRY | 1 | Sep 2, 2015 | clinicaltrials |
| NCT01368003 | STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling | withdrawn | Phase 2 | 0 | Toni Choueiri, MDOTHER | 1 | Sep 1, 2015 | clinicaltrials |
| NCT01312493 | Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | Aug 28, 2015 | clinicaltrials |
| NCT00244348 | Hepatic Artery Infusion With Oxaliplatin | withdrawn | Phase 1 / Phase 2 | 0 | Medical College of WisconsinOTHER | 1 | Aug 27, 2015 | clinicaltrials |
| NCT00620607 | huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas | withdrawn | Phase 2 | 0 | ImmunoGen, Inc.INDUSTRY | 1 | Aug 26, 2015 | clinicaltrials |
| NCT00446173 | Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2015 | clinicaltrials |
| NCT02396433 | Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers | withdrawn | Phase 1 / Phase 2 | 0 | The University of Texas Health Science Center at San AntonioOTHER | 0 | Aug 25, 2015 | clinicaltrials |
| NCT00003605 | Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma | withdrawn | Phase 2 | 0 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT00003663 | Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma | withdrawn | Phase 2 | 0 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Aug 19, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Mar 16, 2016source: clinicaltrials